Abeona’s ZEVASKYN launch creates high asymmetric upside, but manufacturing yields and QTC conversion must improve before the $16.47 probability-weighted five-year target is de-risked.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical enterprise focused on developing and commercializing transformative cell and gene therapies for severe, life-threatening rare genetic disorders [cite: 1, 2, 3]. The company's primary operational focus is centered on its lead asset, ZEVASKYN (prademagene zamikeracel / pz-cel), an autologous cell-based gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) [cite: 4, 5]. Beyond ZEVASKYN, Abeona leverages its end-to-end cellular manufacturing infrastructure to advance ABO-701, an autologous engineered T-cell therapy utilizing a Synthetic Immune Receptor (SIR-T) platform targeting Prostate-Specific Membrane Antigen (PSMA) for advanced prostate cancer [cite: 6, 7]. Additionally, the company maintains out-licensed pipeline assets, including ABO-102 for Sanfilippo syndrome type A, which generate tiered royalty streams and milestone eligibility [cite: 8].
Abeona generates product revenue primarily through the direct sale of ZEVASKYN gene-modified cellular sheets to specialized tertiary medical centers and pediatric health systems [cite: 4, 9]. The company realizes a gross price of approximately $2.85 million to $2.90 million per completed patient treatment [cite: 9]. Product revenue is formally recognized upon the successful delivery and application of the patient-specific cellular sheets [cite: 4, 10]. Non-product revenue historically included Priority Review Voucher (PRV) monetization, such as the $152.4 million gain recorded in 2025 following FDA approval [cite: 11], as well as legacy licensing agreements [cite: 8]. Abeona operates exclusively within the United States, targeting a network of regional Qualified Treatment Centers (QTCs) that specialize in rare genodermatoses [cite: 4, 12].
The primary customer base consists of major academic medical centers and specialized pediatric health systems [cite: 4, 13]. Key activated sites include Children's Hospital of Philadelphia (CHOP), Cincinnati Children's Hospital Medical Center, NewYork-Presbyterian/Columbia University Irving Medical Center, University of Texas Medical Branch (UTMB), and Ann & Robert H. Lurie Children's Hospital of Chicago [cite: 4, 10, 14]. The end market encompasses an estimated 750 moderate-to-severe RDEB patients in the United States who present with chronic, non-healing open wounds and severe tissue fragility resulting from functional mutations in the COL7A1 gene [cite: 3, 12].
Healthcare providers, patients, and payers select ZEVASKYN over competing options—specifically topical re-dosable gene therapies such as Krystal Biotech’s Vyjuvek—because ZEVASKYN offers durable, long-term wound closure and structural skin restoration through a single surgical grafting procedure [cite: 3, 5]. While topical gene therapies require bi-weekly, lifetime applications across widespread body surfaces [cite: 3], ZEVASKYN’s autologous gene-corrected cellular sheets demonstrate multi-year wound healing efficacy, as evidenced by 5-year Phase 3 clinical data and 12-year case report follow-ups showing sustained collagen VII expression and tissue integrity [cite: 6, 13].
Abeona’s main top-line growth driver is the expansion of its commercial ZEVASKYN rollout [cite: 4, 11]. Key growth initiatives focus on three critical operational pillars: expanding the QTC network, increasing biopsy conversion rates, and optimizing cGMP manufacturing throughput [cite: 4, 10, 14]. To drive regional access, management has expanded its activated QTC footprint to seven premier medical centers, establishing in-state access for approximately 40% of the target U.S. addressable patient population [cite: 4, 10]. A major strategic catalyst supporting hospital adoption is the Centers for Medicare & Medicaid Services (CMS) granting New Technology Add-On Payment (NTAP) status for ZEVASKYN under the fiscal year 2027 Hospital Inpatient Prospective Payment System, effective October 1, 2026 [cite: 4, 13]. NTAP provides supplemental hospital reimbursement above the standard Diagnosis-Related Group (DRG) payment, removing financial disincentives for inpatient stays and specialized surgical grafting [cite: 13].
| Product / Platform | Target Indication | Modality / Mechanism | Development / Commercial Stage | Commercial Rights & Economics |
|---|---|---|---|---|
| ZEVASKYN (pz-cel) | Recessive Dystrophic Epidermolysis Bullosa (RDEB) | Autologous retroviral COL7A1 gene-corrected skin sheets | FDA Approved / Commercial Launch | 100% Worldwide Rights; ~$2.85M-$2.90M per treatment [cite: 5, 9] |
| ABO-701 | Advanced Metastatic Prostate Cancer | Autologous SIR-T engineered T-cell therapy targeting PSMA | Preclinical (IND submission targeted H2 2027) | In-licensed from Angeles Therapeutics; Global rights [cite: 6, 7] |
| ABO-102 | Sanfilippo Syndrome Type A (MPS IIIA) | AAV9 gene therapy expressing SGSH enzyme | Out-licensed Clinical Stage | Tiered royalties (mid-single digits to 8%) + $30M milestones [cite: 8] |
The product sold under the ZEVASKYN trade name involves a specialized, 25-day autologous cell-processing service [cite: 10, 14]. Full-thickness skin biopsies collected from an RDEB patient are transported to Abeona's commercial cGMP manufacturing facility in Cleveland, Ohio [cite: 5, 8]. Primary keratinocytes are isolated, expanded, and transduced with a retroviral vector carrying a functional human COL7A1 gene [cite: 3, 5]. The engineered cells are grown into cohesive cellular sheets, packaged, and delivered back to the QTC, where surgeons graft them onto large, chronic non-healing wounds during a scheduled surgical procedure [cite: 3, 5].
Abeona’s economic moat relies on intellectual property, steep switching costs, and specialized clinical infrastructure [cite: 4, 8, 10]. The proprietary manufacturing processes developed for cell sheet handling represent trade secret protection, while FDA Orphan Drug Designation and Rare Pediatric Disease Designation provide 7 years of post-approval market exclusivity [cite: 15]. Switching costs are high because once a patient undergoes surgical grafting with ZEVASKYN and achieves durable wound closure, the treatment does not require repeated administration at that specific site [cite: 5, 6]. Furthermore, QTC activation requires months of surgical training, pharmacy onboarding, and institutional review, establishing sticky relationships with academic medical centers [cite: 4, 10].
The Total Addressable Market (TAM) for ZEVASKYN in the United States is anchored by an estimated 750 eligible moderate-to-severe RDEB patients who possess active open wounds exceeding 20 cm² in surface area [cite: 12]. At a realized price point of ~$2.85 million per treatment, the U.S. TAM represents a market value exceeding $2.1 billion [cite: 9, 12]. Expansion into international markets, such as Europe and Japan, represents a broader global addressable market opportunity exceeding $4.0 billion [cite: 5, 15].
The competitive landscape in RDEB is split between topical re-dosable therapies and definitive surgical cellular grafts [cite: 3]. Krystal Biotech’s Vyjuvek (approved in 2023) is a redosable topical HSV-1 vector gene therapy designed for weekly application to smaller or recurrent blisters [cite: 3, 5]. Vyjuvek holds market share for routine wound care management [cite: 3]. However, ZEVASKYN does not compete directly for minor wound maintenance; instead, it holds a specialized position in treating large, refractory chronic wounds that present continuous infection risks and systemic burden [cite: 3, 12]. Surgical cellular sheets provide structural skin restoration where topical vectors fail to heal deeper lesions [cite: 3, 5]. Alternative approaches, such as INmune Bio’s pre-clinical CORDStrom, remain early-stage and pose limited immediate competitive risk [cite: 15].
Abeona reported its latest quarterly financial results for Q2 2026 (ended June 30, 2026) on August 13, 2026 [cite: 4, 16]. During the quarter, the company generated net ZEVASKYN product revenue of $11.38 million, representing a 30.5% sequential increase over Q1 2026 product revenue of $8.72 million [cite: 4, 9]. Total revenue for the six months ended June 30, 2026, reached $20.10 million, compared to $0.40 million in non-product license revenue in the prior-year period [cite: 4, 17].
| Metric | Q2 2026 Actual | Q2 2026 Consensus Estimate | Variance / Beat (Miss) | Q1 2026 Actual | Q2 2025 Actual |
|---|---|---|---|---|---|
| Net Product Revenue | $11.38M [cite: 4] | $12.24M [cite: 16] | $(0.86)M / Miss [cite: 10, 16] | $8.72M [cite: 9] | $0.00M [cite: 4] |
| GAAP Net Income (Loss) | $(20.19)M [cite: 4] | N/A | N/A | $(17.08)M [cite: 10] | $108.83M [cite: 4] |
| GAAP EPS | $(0.35) [cite: 4] | $(0.23) [cite: 16] | $(0.12) / Miss [cite: 10, 16] | $(0.30) [cite: 9] | $1.71 [cite: 14, 16] |
| Gross Margin % | 63.3% [cite: 4, 10] | N/A | N/A | 69.0% [cite: 9] | N/A |
| R&D Expenses | $5.02M [cite: 4] | N/A | N/A | $9.56M [cite: 18] | $5.94M [cite: 4] |
| SG&A Expenses | $15.84M [cite: 4] | N/A | N/A | $19.50M [cite: 4] | $17.15M [cite: 4] |
| Cash & Investments | $146.83M [cite: 4] | N/A | N/A | $168.30M [cite: 6] | $225.90M [cite: 14] |
Q2 2026 revenue of $11.38 million missed consensus expectations of $12.24 million by $0.86 million, while GAAP EPS of -$0.35 missed consensus estimates of -$0.23 by $0.12 [cite: 10, 16]. The quarterly net loss widened to $20.19 million, driven by commercial launch investments and a $7.2 million non-cash loss associated with changes in the fair value of warrant liabilities [cite: 4, 19]. Operating loss narrowed year-over-year to $13.65 million compared to $22.79 million in Q2 2025 [cite: 4].
Management did not issue formal quantitative full-year revenue guidance updates but reiterated operational target metrics during the earnings call [cite: 11, 20]. Management affirmed that reaching an operational cadence of 3.5 or more patient treatments per month—equivalent to ~$100 million in annual product revenue—represents the breakeven threshold for corporate cash flow [cite: 9, 11]. Management highlighted several commercial learnings:
1. Five patients were treated in Q2 2026, but revenue was recognized for four due to one batch suffering from low manufacturing yield [cite: 4, 10].
2. In Q3 2026 to date, three patients completed treatment, with one batch failing lot release specifications, preventing revenue recognition [cite: 10, 19].
3. Patient health volatility caused last-minute biopsy delays, underscoring friction in converting scheduled biopsies into completed commercial treatments [cite: 10].
4. Current gross margins of ~63.3% are expected to expand toward 85%–90% as fixed Cleveland manufacturing overhead is absorbed across higher patient volumes [cite: 10, 20].
Following the August 13, 2026 earnings release, Abeona’s stock price experienced an immediate sell-off, declining 11.0% to 15.0% in pre-market and regular session trading as investors digested the revenue miss and manufacturing yield issues [cite: 19, 20, 21]. Despite the short-term drop, sell-side analysts maintained positive outlooks [cite: 1, 9, 20]. Oppenheimer adjusted its price target from $22.00 to $21.00 while maintaining an Outperform rating [cite: 20, 21]. Roth/MKM maintained coverage with a Buy rating and a $17.00 price target [cite: 20], Stifel reaffirmed its Buy rating and $17.00 price target [cite: 20], and Cantor Fitzgerald adjusted its target upward to $30.00 following positive clinical partner updates [cite: 22].
At a share price of $5.60, Abeona trades at a basic Market Capitalization of ~$320.3 million and an Enterprise Value (EV) of ~$188.5 million, taking into account $146.83 million in cash and short-term investments alongside $15.0 million in long-term debt [cite: 4, 17, 18]. Based on current forward revenue estimates ($54.3 million for FY2026 and $118.9 million for FY2027), the stock trades at forward Price-to-Sales (P/S) multiples of 6.3x FY2026 sales and 2.9x FY2027 sales [cite: 18]. Trailing P/S stands at 13.4x [cite: 18].
The primary financial drivers dictating valuation over the next 5 years include 5-year sales CAGR (projected at 40%–45%), gross margin expansion from 63% to 85%+, operating expense stabilization as commercial infrastructure scales, and cash flow management [cite: 10, 18, 20, 23].
A detailed assessment of Abeona’s risk profile reveals several structural operational, competitive, and macroeconomic dynamics that require close investor tracking across multiple operational categories.
The primary operational risk stems from autologous cell manufacturing yield variability and stringent batch release criteria [cite: 10]. Because ZEVASKYN uses patient-derived skin biopsies, biological variability in starting tissue quality can result in low cell yield or lot release failures, as seen in Q2 and Q3 2026 [cite: 10]. Unrecognized treatments burn high fixed costs without producing revenue, compressing gross margins [cite: 4, 10]. Additionally, scheduling biopsies remains vulnerable to patient health volatility; severe skin infections or systemic complications in RDEB patients frequently lead to delayed or cancelled procedures [cite: 10].
While ZEVASKYN holds a differentiated position for large, severe chronic wounds, Krystal Biotech’s Vyjuvek enjoys first-mover advantage, established reimbursement channels, and a non-invasive topical administration route [cite: 3]. If physicians and patients prefer topical applications over surgical hospitalization, ZEVASKYN’s commercial addressable market could narrow strictly to tertiary surgical refractory cases, capping peak penetration [cite: 3, 5].
Commercial execution relies on a small group of specialized medical institutions [cite: 4, 10]. With seven activated QTCs, institutional disruption, surgical staff turnover, or administrative bottlenecks at a top-tier center (such as CHOP or Cincinnati Children’s) would impact quarterly treatment volume and net revenue [cite: 4, 10, 13]. Furthermore, the total U.S. eligible candidate base (~750 patients) requires commercial targeting to maintain treatment momentum [cite: 12].
Abeona relies on a single cGMP manufacturing facility in Cleveland, Ohio [cite: 8, 14]. Any Form 483 observational findings, warning letters, or facility shutdowns enforced by the FDA would halt commercial production [cite: 14]. Furthermore, as a retroviral-transduced autologous therapy, ZEVASKYN carries long-term post-marketing regulatory obligations to monitor patients for potential insertional mutagenesis or secondary oncogenic events [cite: 3, 5].
During the six months ended June 30, 2026, Abeona burned $37.3 million in operating cash flows [cite: 17]. Although its $146.8 million cash balance provides approximately 18 to 24 months of operational runway [cite: 4, 17], failure to reach the 3.5 patient per month breakeven threshold by late 2027 would force the company to execute dilutive equity financings or raise debt, diluting existing equity holders [cite: 9, 11, 19].
With a price tag of ~$2.85 million per treatment, ZEVASKYN is vulnerable to healthcare cost-containment efforts, commercial payer pre-authorization delays, and state Medicaid budget caps [cite: 4, 9, 13]. Furthermore, short interest (~25% of basic shares outstanding) exposes the stock to elevated volatility during broader biotech risk-off market environments [cite: 18].
An analysis of potential failure modes reveals distinct operational indicators. The primary scenario that could go wrong involves autologous manufacturing yield issues persisting above 15% of processed batches, causing QTC surgeons to lose operational confidence and defer patient scheduling [cite: 10]. Early warning signs of thesis deterioration would include sequential quarterly flatlining in recognized patient treatments, gross margins dropping below 60%, or delayed activation of planned QTC sites [cite: 4, 10]. The events that would damage the long-term thesis are a severe clinical safety signal (such as retrovirus-induced malignancy), permanent FDA regulatory suspension of the Cleveland cGMP facility, or a structural inability to convert biopsy volume into recognized commercial revenue [cite: 8, 10, 14].
To model Abeona’s 5-year total return profile, a financial projection (2026–2031) was constructed using the current share price of $5.60, a current basic share count of 57.23 million, and a fully diluted share base of 71.10 million shares (incorporating options, restricted stock units, and warrants) [cite: 1, 19, 24].
In the Base Case Scenario (assigned a 55% probability), ZEVASKYN executes a steady commercial rollout, expanding the U.S. network to 12 QTCs and launching in select European markets [cite: 4, 5]. Patient treatment velocity scales to approximately 75 patients treated per year globally by Year 5 (~6.25 per month) at a net price of $2.80 million per patient [cite: 9, 11]. ABO-701 completes Phase 1 clinical trials and enters Phase 2 testing in prostate cancer [cite: 6]. Manufacturing gross margins reach steady-state targets of 85.0% [cite: 10, 20]. This yields Year 5 revenue of $210.0 million and a net margin of 28.0%, resulting in $58.8 million in net income. Applying a 16.0x P/E multiple (equivalent to ~4.5x P/S) on a fully diluted share count of 78.0 million yields an implied future market cap of $940.8 million and a share price of $12.06 USD, representing a 115.4% total return (16.6% CAGR).
In the High Case Scenario (assigned a 25% probability), commercial adoption accelerates due to hospital integration driven by CMS NTAP reimbursement status [cite: 4, 13]. The QTC network expands to 15 sites in the U.S. alongside full European and Japanese commercial distribution [cite: 5]. ZEVASKYN reaches 130 patient treatments per year globally by Year 5 (~10.8 per month) [cite: 14]. ABO-701 generates Phase 1/2 clinical efficacy, leading to a major co-development partnership [cite: 6]. Year 5 revenue reaches $364.0 million with an 88.0% gross margin and a 36.0% net margin, producing $131.0 million in net income. Applying a 22.0x P/E multiple (equivalent to ~7.9x P/S) on 74.0 million shares yields an implied market cap of $2,882.0 million and a share price of $38.95 USD, representing a 595.5% total return (47.3% CAGR).
In the Low Case Scenario (assigned a 20% probability), severe commercial friction persists [cite: 10]. Manufacturing yield issues continue, batch rejections remain near 15%–20%, and patient health volatility limits treatment scheduling [cite: 10]. Vyjuvek retains market dominance for RDEB care [cite: 3]. ZEVASKYN treats only 25 patients per year by Year 5 (~2.1 per month). ABO-701 fails to demonstrate efficacy in clinical trials and is terminated [cite: 6]. Abeona is forced to execute dilutive capital raises at low valuations [cite: 17, 25]. Year 5 revenue reaches $70.0 million with a 65.0% gross margin and a 6.0% net margin, generating $4.2 million in net income. Applying a 12.0x P/E multiple on a expanded share base of 105.0 million shares yields an implied market cap of $50.4 million and a share price of $0.48 USD, representing a -91.4% total return (-38.3% CAGR).
| Year / Horizon | Base Case Share Price (USD) | High Case Share Price (USD) | Low Case Share Price (USD) |
|---|---|---|---|
| Year 0 (2026 Current) | $5.60 | $5.60 | $5.60 |
| Year 1 (2027) | $6.50 | $9.50 | $3.50 |
| Year 2 (2028) | $7.80 | $14.80 | $2.10 |
| Year 3 (2029) | $9.20 | $21.50 | $1.20 |
| Year 4 (2030) | $10.60 | $29.80 | $0.75 |
| Year 5 (2031) | $12.06 | $38.95 | $0.48 |
| Scenario | Revenue in Year 5 | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price | Implied Future Share Price | 5-Year Total Return | Annualized Return | Probability |
|---|---|---|---|---|---|---|---|---|
| Base Case | $210.0M | 28.0% Net Margin ($58.8M Net Income) | 16.0x P/E | $5.60 USD | $12.06 USD | +115.4% | 16.6% | 55% |
| High Case | $364.0M | 36.0% Net Margin ($131.0M Net Income) | 22.0x P/E | $5.60 USD | $38.95 USD | +595.5% | 47.3% | 25% |
| Low Case | $70.0M | 6.0% Net Margin ($4.2M Net Income) | 12.0x P/E | $5.60 USD | $0.48 USD | -91.4% | -38.3% | 20% |
| Weighted Target | $220.3M | 25.6% Net Margin ($56.3M Net Income) | 16.7x P/E | $5.60 USD | $16.47 USD | +194.1% | 24.1% | 100% |
Calculating the probability-weighted share price outcome across all three operational trajectories yields a 5-year expected target price of $16.47 USD, representing a probability-weighted total return of +194.1% (24.1% annualized return).
ATTRACTIVE ASYMMETRIC UPSIDE.
| Assessment Dimension | Score (1-10) | Narrative Justification & Qualitative Analysis |
|---|---|---|
| Management Alignment | 6 / 10 | CEO Dr. Vish Seshadri directly owns 2.28% of outstanding shares (~$7.1M value) [cite: 26, 27]. While executive compensation is weighted toward stock and performance milestones, ongoing net insider sales ($3.0M net sold over trailing 12 months) slightly temper alignment [cite: 26, 27]. |
| Revenue Quality | 7 / 10 | High realized net price per patient (~$2.85M) backed by 95% commercial life coverage and CMS NTAP reimbursement status [cite: 6, 9, 13]. However, revenue is non-recurring per individual patient [cite: 4, 10]. |
| Market Position | 6 / 10 | Holds an exclusive position as the sole FDA-approved autologous cell therapy for severe RDEB wounds [cite: 3, 5]. However, it holds secondary market volume share relative to Krystal Biotech's non-invasive topical Vyjuvek [cite: 3]. |
| Growth Outlook | 8 / 10 | Substantial top-line scaling potential as commercial adoption ramps from $0 in 2025 to projected $50M+ in 2026 and $100M+ near breakeven thresholds [cite: 9, 11, 18]. |
| Financial Health | 6 / 10 | Robust balance sheet holding $146.8M in cash and investments against $15.0M in long-term debt [cite: 4, 17]. Offset by significant operational cash burn ($37.3M in 1H 2026) [cite: 17]. |
| Business Viability | 7 / 10 | Technological foundation supported by multi-year clinical durability data [cite: 6]. Proprietary Cleveland manufacturing facility provides structural moat, though batch yield volatility represents an operational choke point [cite: 10, 14]. |
| Capital Allocation | 6 / 10 | Portfolio optimization demonstrated by deprioritizing early-stage ophthalmology assets to focus cash on ZEVASKYN launch and high-upside ABO-701 oncology asset [cite: 6]. |
| Analyst Sentiment | 9 / 10 | Wall Street consensus is bullish, maintaining Buy/Outperform recommendations with price targets ranging from $17.00 to $30.00 [cite: 1, 9, 20, 22]. |
| Profitability | 4 / 10 | Currently unprofitable with ongoing operating losses [cite: 4]. However, current gross margins (~63%) provide operational leverage toward management's 85%–90% target [cite: 10, 20]. |
| Track Record | 4 / 10 | Historical shareholder returns have been volatile due to past regulatory delays [cite: 1, 23]. Management redeemed credibility by securing FDA approval for ZEVASKYN and monetizing a PRV for $152.4 million [cite: 5, 11]. |
Blended Overall Score: 6.3 / 10
This qualitative scorecard is presented exclusively for educational analysis and does not constitute financial advice or an investment recommendation.
COMMERCIAL TRANSITION PHASE.
Abeona Therapeutics presents a commercial-stage investment profile characterized by operational leverage and valuation asymmetry [cite: 4, 18]. The commercial approval and initial launch of ZEVASKYN establish Abeona as a commercial cell therapy provider addressing a high-unmet-need rare disease market [cite: 3, 5]. While the company missed consensus estimates in Q2 2026 due to autologous manufacturing yield issues and patient health volatility [cite: 10, 16], the structural demand for long-term wound healing in RDEB remains present [cite: 3, 12].
The core investment narrative rests on three main catalysts over the next 12 to 24 months:
1. CMS NTAP Implementation: Effective October 1, 2026, NTAP status provides supplemental Medicare reimbursement, facilitating hospital inpatient adoption and removing administrative reimbursement barriers [cite: 4, 13].
2. QTC Expansion & Operational Breakeven: Expanding active QTCs to 10+ sites and driving treatment cadence above 3.5 patients per month (~$100 million annual revenue run rate) will transition Abeona to operational cash flow breakeven, preserving cash reserves [cite: 9, 11, 13].
3. Pipeline Progress (ABO-701): Advancing ABO-701 (PSMA SIR-T CAR-T candidate) toward an IND filing in H2 2027 expands the platform into solid tumor oncology [cite: 6, 7].
Key risks include ongoing batch release rejections, manufacturing yield volatility, and commercial competition from non-invasive topical therapies [cite: 3, 10]. However, at an Enterprise Value of ~$188 million and a probability-weighted 5-year price target of $16.47 USD, the risk/reward asymmetry reflects potential appreciation for long-term investors as commercial scaling matures [cite: 17, 18].
This investment analysis report is provided strictly for educational and informational purposes and under no circumstances represents personalized financial advice or a recommendation to buy, sell, or hold securities.
HIGH ASYMMETRIC POTENTIAL.
Abeona Therapeutics (ABEO) is currently trading around $5.60 per share, consolidating near its 200-day moving average ($5.44–$5.48) and holding support established at $5.49 [cite: 2, 24, 28]. The 14-day Relative Strength Index (RSI) stands at 55.3, signaling neutral technical momentum [cite: 28]. While the Q2 2026 revenue miss induced short-term pullbacks from $6.64 levels [cite: 20], the stock maintains horizontal support above $5.49, with primary overhead resistance at $6.07 [cite: 24]. Near-term price action is likely to remain range-bound until the implementation of CMS NTAP reimbursement on October 1, 2026, which serves as the next fundamental catalyst for potential technical breakout [cite: 4, 13, 24].
CONSOLIDATING ABOVE SUPPORT.
View Abeona Therapeutics Inc. (ABEO) stock page
Loading the interactive version of this report…